Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy

01-08-2014 | Original Research Article

Association of Rho-kinase 1 (ROCK1) Gene Polymorphisms with Behçet’s Disease

Published in: Molecular Diagnosis & Therapy | Issue 4/2014

Login to get access

Abstract

Background and Objective

Behçet’s disease (BD) is a chronic inflammatory vasculitis presenting with flares and silent periods usually between 15 and 40 years of age. The aim of this study was to evaluate the possible association between Rho-kinase 1 (ROCK1) gene polymorphisms and patients with BD in a Turkish population.

Methods

A total of 192 BD patients and 255 healthy controls of similar age and sex were enrolled in this study. Polymorphisms were analyzed in genomic DNA using a BioMark HD dynamic array system.

Results

In the presence of CC genotype for rs73963110, CT genotype for rs111874856 (Val355Ile), and TC genotype for rs112130712 (Lys1054Arg) polymorphisms, the risk of BD increased 12.13-, 15.05-, and 16.28-fold, respectively (p < 0.0001). There was a lower frequency of the GA genotype of the rs112108028 (Pro1164Leu) polymorphisms in BD (10.3 %) compared with controls (39.7 %; p < 0.0001). Marked associations between these polymorphisms and the manifestations of BD were recorded.

Conclusion

This is the first study to show that ROCK1 gene polymorphisms may have a significant impact on susceptibility to BD.
Literature
1.
2.
Haznedaroglu IC, Ozcebe OI, Ozdemir O, et al. Impaired haemostatic kinetics and endothelial function in Behçet’s disease. J Intern Med. 1996;240(4):181–7.PubMedCrossRef
3.
Kiraz S, Ertenli I, Oztürk MA, et al. Pathological haemostasis and “prothrombotic state” in Behçet’s disease. Thromb Res. 2002;105(2):125–33.PubMedCrossRef
4.
Acikgoz N, Ermiş N, Yağmur J, et al. Elevated oxidative stress markers and its relationship with endothelial dysfunction in Behçet disease. Angiology. 2011;62(4):296–300.PubMedCrossRef
5.
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078–80.
6.
Keogan MT. Clinical ımmunology review series: an approach to the patient with recurrent orogenital ulceration, including Behçet’s syndrome. Clin Exp Immunol. 2009;156(1):1–11.PubMedCentralPubMedCrossRef
7.
Mendoza-Pinto C, García-Carrasco M, Jiménez-Hernández M, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9(4):241–5.PubMedCrossRef
8.
Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15(8):1885–93.PubMedCentralPubMed
9.
Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15(9):2208–16.PubMedCentralPubMed
10.
Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4(6):446–56.PubMedCrossRef
11.
12.
Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011;32(3):167–73.PubMedCentralPubMedCrossRef
13.
Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol. 2002;39(4–5):187–99.PubMedCrossRef
14.
Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol. 2001;21(5):868–73.PubMedCrossRef
15.
Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93(8):767–75.PubMedCrossRef
16.
Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22(24):8467–77.PubMedCentralPubMedCrossRef
17.
Mizuki N, Ota M, Yabuki K, et al. Localization of the pathogenic gene of Behçet’s disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci. 2000;41(12):3702–8.PubMed
18.
Gül A, Hajeer AH, Worthington J, et al. Evidence for linkage of the HLA-B locus in Behçet’s disease, obtained using the transmission disequilibrium test. Arthritis Rheum. 2001;44(1):239–40.PubMedCrossRef
19.
Oguz E, Alasehirli B, Pehlivan Y, et al. Association between Rho-kinase (ROCK2) gene polymorphisms and Behçet’s disease. Transl Res. 2012;160(6):428–34.PubMedCrossRef
20.
21.
Karasneh J, Gül A, Ollier WE, et al. Whole-genome screening for susceptibility genes in multicase families with Behçet’s disease. Arthritis Rheum. 2005;52(6):1836–42.PubMedCrossRef
22.
Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Behçet’s disease using a genome-wide association study. Arthritis Res Ther. 2009;11(3):R66.PubMedCentralPubMedCrossRef
23.
Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42(8):698–702.PubMedCentralPubMedCrossRef
24.
Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol. 1982;100(9):1455–8.PubMedCrossRef
25.
Piga M, Mathieu A. Genetic susceptibility to Behcet’s disease: role of genes belonging to the MHC region. Rheumatology (Oxford). 2011;50(2):299–310.PubMedCrossRef
26.
27.
Palomino Doza J, Topf A, Bentham J, et al. Low-frequency intermediate penetrance variants in the ROCK1 gene predispose to Tetralogy of Fallot. BMC Genet. 2013;14:57.
28.
Sari I, Berberoglu B, Ozkara E, et al. Role of rho-kinase gene polymorphisms and protein expressions in colorectal cancer development. Pathobiology. 2013;80(3):138–45.PubMedCrossRef
29.
Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol. 2005;50(4):297–350.PubMedCrossRef
30.
Bekpinar S, Kiliç N, Unlüçerçi Y, et al. Evaluation of nitrosative and oxidative stress in Behçet disease. J Eur Acad Dermatol Venereol. 2005;19(2):167–71.PubMedCrossRef
31.
Akcay YD, Sagin FG, Aksu K, et al. A panel of oxidative stress assays does not provide supplementary diagnostic information in Behcet’s disease patients. J Inflamm (Lond). 2012;9:13.PubMedCentralCrossRef
32.
Onur E, Kabaroglu C, Inanir I, et al. Oxidative stress impairs endothelial nitric oxide levels in Behçet’s disease. Cutan Ocul Toxicol. 2011;30(3):217–20.PubMedCrossRef
33.
Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol. 2004;287(4):H1495–500.PubMedCrossRef
34.
Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39(2):245–50.PubMedCrossRef
35.
Shah DI, Singh M. Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol Cell Biochem. 2006;283(1–2):191–9.PubMedCrossRef
36.
Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome. Int J Dermatol. 2003;42(11):870–5.PubMedCrossRef
37.
Erdem F, Gündoğdu M, Kiki I, et al. Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet’s disease. Rheumatol Int. 2005;25(8):599–603.PubMedCrossRef
38.
Sun H, Breslin JW, Zhu J, et al. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation. 2006;13(3):237–47.PubMedCrossRef
39.
van Nieuw Amerongen GP, Koolwijk P, Versteilen A, et al. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol. 2003;23(2):211–7.
40.
Zierhut M, Abu El-Asrar AM, Bodaghi B, et al. Therapy of ocular Behçet disease. Ocul Immunol Inflamm. 2014;22(1):64–76.
41.
42.
Rubenstein NM, Callahan JA, Lo DH, et al. Selective glucocorticoid control of Rho kinase isoforms regulate cell-cell interactions. Biochem Biophys Res Commun. 2007;354(2):603–7.PubMedCentralPubMedCrossRef
Metadata
Title
Association of Rho-kinase 1 (ROCK1) Gene Polymorphisms with Behçet’s Disease
Publication date
01-08-2014
Published in
Molecular Diagnosis & Therapy / Issue 4/2014
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-014-0092-5
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits